(NASDAQ: NCNA) Nucana's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Nucana's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NCNA's revenue for 2025 to be $158,581,005, with the lowest NCNA revenue forecast at $158,581,005, and the highest NCNA revenue forecast at $158,581,005. On average, 1 Wall Street analysts forecast NCNA's revenue for 2026 to be $475,743,015, with the lowest NCNA revenue forecast at $475,743,015, and the highest NCNA revenue forecast at $475,743,015.
In 2027, NCNA is forecast to generate $3,687,008,366 in revenue, with the lowest revenue forecast at $951,486,030 and the highest revenue forecast at $6,422,530,703.